Breaking News Instant updates and real-time market news.

CELG

Celgene

$94.39

2.41 (2.62%)

09:38
02/15/18
02/15
09:38
02/15/18
09:38

Celgene says OTEZLA data shows 'clinically meaningful improvements' in patients

Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at least one conventional therapy but were naive to biologic therapy were presented in an oral session today at the 13th Congress of ECCO in Vienna. The results showed that a higher proportion of patients taking apremilast 30 mg twice daily achieved clinical remission versus placebo. OTEZLA is Celgene's oral selective inhibitor of phosphodiesterase 4. In the study, a total of 170 patients were randomized to placebo, apremilast 40 mg BID or apremilast 30 mg BID. The primary endpoint of the study was Total Mayo Score clinical remission at week 12 for the 40 mg BID arm. At week 12, TMS clinical remission was achieved by 21.8% of patients in the apremilast 40 mg BID arm versus 13.8% in the placebo group. In the apremilast 30 mg BID arm, 31.6% of patients achieved clinical remission as measured by TMS at week 12 versus 13.8% in the placebo group. Clinical remission as measured by Partial Mayo Score, a secondary endpoint, was achieved by 59.6% of patients in the apremilast 30 mg BID arm versus 36.2% in the placebo arm at week 12. PMS clinical remission was also achieved by 52.7% of patients in the apremilast 40 mg BID arm. Additional secondary endpoints examined in the trial, including endoscopic remission, TMS clinical response, serum biomarkers and mucosal healing, showed clinically meaningful improvements for apremilast 30 mg BID versus placebo. Treatment-emergent adverse events reported in at least 5% of patients treated with apremilast included headache; viral upper respiratory tract infection; nausea; abdominal pain; back pain; and asthenia. Apremilast is not approved for the treatment of ulcerative colitis in any country. In January 2018, the U.S. Food and Drug Administration designated apremilast an Orphan Drug for the potential treatment of pediatric patients with ulcerative colitis.

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 25

    Mar

  • 30

    May

CELG Celgene
$94.39

2.41 (2.62%)

02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/18
LEHM
02/13/18
UPGRADE
Target $105
LEHM
Overweight
Celgene upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Celgene to Overweight with an unchanged price target of $105. The analyst remains concerned about Revlimid concentration risk long-term, but says the current valuation largely reflects the risk. Since the highs in October 2017, the stock has dropped $55 per share, Meacham tells investors in a research note. He notes Celgene's risk/reward profile based on his net present value analysis yields an "attractive upside case."
02/09/18
PIPR
02/09/18
NO CHANGE
PIPR
Piper Jaffray reiterates Outperform on Crispr after CSO departure
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $39 price target on Crispr Therapeutics, despite Crispr trading down over 13% on news that Dr. Bill Lundberg is stepping down as Chief Scientific Officer and Celgene (CELG) has reduced its stake in the company to 6.1% from 8.0%. Tenthoff said he remains focused on Crispr's "therapeutic opportunity with first-in-man CTX001 Beta thalassemia and potentially sickle cell disease data this year."
01/29/18
WELS
01/29/18
NO CHANGE
Target $23
WELS
Outperform
Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.

TODAY'S FREE FLY STORIES

02:35
12/11/18
12/11
02:35
12/11/18
02:35
General news
FX Update: Narrow ranges have prevailed so far today »

FX Update: Narrow ranges…

02:05
12/11/18
12/11
02:05
12/11/18
02:05
General news
FX Action: USD-JPY has settled in the lower 113.0s »

FX Action: USD-JPY has…

01:45
12/11/18
12/11
01:45
12/11/18
01:45
General news
Breaking General news story  »

4-Week Bill Settlement to…

01:40
12/11/18
12/11
01:40
12/11/18
01:40
General news
Asian Market Wrap: »

Asian Market Wrap:…

SCL

Stepan Company

$75.84

0.62 (0.82%)

21:26
12/10/18
12/10
21:26
12/10/18
21:26
Initiation
Stepan Company initiated at Stifel »

Stepan Company initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

21:25
12/10/18
12/10
21:25
12/10/18
21:25
Conference/Events
Morgan Stanley semiconductors analysts to hold analyst/industry conference call »

U.S. Semiconductors…

POL

PolyOne

$30.74

-0.24 (-0.77%)

21:17
12/10/18
12/10
21:17
12/10/18
21:17
Initiation
PolyOne initiated at Stifel »

PolyOne initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLN

Olin

$20.32

0.14 (0.69%)

21:14
12/10/18
12/10
21:14
12/10/18
21:14
Initiation
Olin initiated at Stifel »

Olin initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRA

Kraton

$24.26

0.3 (1.25%)

21:07
12/10/18
12/10
21:07
12/10/18
21:07
Initiation
Kraton initiated at Stifel »

Kraton initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HT

Hersha Hospitality

$18.49

-0.27 (-1.44%)

20:57
12/10/18
12/10
20:57
12/10/18
20:57
Downgrade
Hersha Hospitality rating change at Wells Fargo »

Hersha Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARS

Cars.com

$23.94

-0.37 (-1.52%)

20:53
12/10/18
12/10
20:53
12/10/18
20:53
Hot Stocks
Cars.com responds to letter from Starboard Value fund »

Cars.com states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERI

Veritone

$6.90

1.28 (22.78%)

20:49
12/10/18
12/10
20:49
12/10/18
20:49
Hot Stocks
Veritone confirms unsolicited bid from Apis Capital »

Veritone confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGVT

Ingevity

$86.46

1.31 (1.54%)

20:47
12/10/18
12/10
20:47
12/10/18
20:47
Initiation
Ingevity initiated at Stifel »

Ingevity initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$41.36

-0.36 (-0.86%)

20:38
12/10/18
12/10
20:38
12/10/18
20:38
Initiation
H.B. Fuller initiated at Stifel »

H.B. Fuller initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$72.77

-0.36 (-0.49%)

20:29
12/10/18
12/10
20:29
12/10/18
20:29
Initiation
Eastman Chemical initiated at Stifel »

Eastman Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$23.04

-1.19 (-4.91%)

20:25
12/10/18
12/10
20:25
12/10/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CE

Celanese

$89.79

-1.445 (-1.58%)

20:24
12/10/18
12/10
20:24
12/10/18
20:24
Initiation
Celanese initiated at Stifel »

Celanese initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASIX

AdvanSix

$25.33

0.18 (0.72%)

20:18
12/10/18
12/10
20:18
12/10/18
20:18
Initiation
AdvanSix initiated at Stifel »

AdvanSix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWW

Grainger

$285.60

-3.88 (-1.34%)

20:11
12/10/18
12/10
20:11
12/10/18
20:11
Initiation
Grainger initiated at Buckingham »

Grainger initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

NFLX

Netflix

$269.80

4.66 (1.76%)

20:00
12/10/18
12/10
20:00
12/10/18
20:00
Initiation
Netflix initiated at DZ Bank »

Netflix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$0.00

(0.00%)

19:12
12/10/18
12/10
19:12
12/10/18
19:12
Periodicals
Vivendi seeks to invest in Trump partner's Indonesia TV unit, Bloomberg says »

Vivendi is seeking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

, GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

19:05
12/10/18
12/10
19:05
12/10/18
19:05
Periodicals
Human rights orgs urge Google to not launch censored app in China, Verge says »

Dozens of human rights…

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 03

    Mar

ASNA

Ascena Retail

$2.73

-0.28 (-9.30%)

, ASPU

Aspen Group

$5.66

-0.14 (-2.41%)

18:59
12/10/18
12/10
18:59
12/10/18
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$2.73

-0.28 (-9.30%)

ASPU

Aspen Group

$5.66

-0.14 (-2.41%)

CARS

Cars.com

$23.94

-0.37 (-1.52%)

TROX

Tronox

$7.05

-0.25 (-3.42%)

CR

Crane

$78.23

-0.99 (-1.25%)

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

CASY

Casey's General Stores

$119.64

-1.78 (-1.47%)

NX

Quanex

$14.05

-0.13 (-0.92%)

CAMP

CalAmp

$17.02

-0.23 (-1.33%)

RARX

RA Pharmaceuticals

$17.58

1.13 (6.87%)

SAEX

SAExploration

$3.33

-0.11 (-3.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

  • 12

    Dec

TROX

Tronox

$7.05

-0.25 (-3.42%)

18:46
12/10/18
12/10
18:46
12/10/18
18:46
Hot Stocks
Tronox CEO discloses purchase of 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGT

Allegiant Travel

$124.89

-1.45 (-1.15%)

18:37
12/10/18
12/10
18:37
12/10/18
18:37
Hot Stocks
Allegiant reports November total systems traffic up 10.1% »

Reports total systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.